Engineered Immune Cells Show Promise in Treating Autoimmune Conditions

Scientists at UC San Francisco have developed a new approach to modulate immune responses using engineered T cells. These cells act as "referees" to sooth overreacting immune responses and reduce inflammation. The technology could potentially improve treatments for organ transplants, type 1 diabetes, and other autoimmune conditions without the need for harsh immunosuppressant drugs. 

The researchers adapted the anti-inflammatory abilities of natural suppressor cells and incorporated them into CD4 immune cells, similar to those used in CAR T cell cancer therapies. They also equipped these cells with molecular sensors to guide them to specific target tissues in the body.

In a proof-of-principle study for type 1 diabetes, the team created immune referee cells designed to protect human pancreatic islet cells. When introduced into mice with transplanted human islet cells, these engineered cells successfully prevented killer T cells from attacking the islets.

“It would be life changing for people with type 1 diabetes if they could get new islet cells without needing to take immunosuppressants, and stop having to take insulin every day,” said Audrey Parent, co-senior author of the paper published in Science.

This approach could lead to more targeted treatments for autoimmune diseases and organ transplant patients, potentially avoiding the side effects associated with general immunosuppressants. The technology might also be used to refine CAR T cell therapies for cancer, ensuring they only target tumors and not healthy tissue.